Globe Newswire

Exceeded Revenue and Adjusted EBITDA Guidance for Q1 2024. Improved Business Momentum in Q1 2024.

Record Low Quarterly Cash Consumption in Q1 2024.

Reiterates Expectation for Revenue Growth and Free Cash Flow Breakeven in FY 2024.

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. (“Rent the Runway” or "RTR") (NASDAQ: RENT), the world’s first and largest shared designer closet platform, today reported financial results for the fiscal... (continue reading...)

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at 1:55 p.m. ET.

A live... (continue reading...)

CORONA, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) announced today that the Company will host a live webcast of its Annual Meeting of Stockholders on Thursday, June 13, 2024. The live webcast will start at 2:30 p.m. Pacific Time.

A live webcast of the Annual Meeting can be accessed through www.virtualshareholdermeeting.com/MNST2024.For those who are not able to listen to the live webcast, the event will be archived for... (continue reading...)

CALGARY, Alberta, June 06, 2024 (GLOBE NEWSWIRE) -- Direct Energy Regulated Services has announced default natural gas rates for June 2024. These rates will apply to customers who have not chosen a competitive supplier within the ATCO Gas North and South service territories. The rates have been verified by the Alberta Utilities Commission.

North Service TerritoryThe North territory includes customers living in and north of the City of Red Deer.•        ... (continue reading...)

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and... (continue reading...)